PCI 34051

Pricing Availability   Qty
Description: Potent and selective HDAC8 inhibitor
Chemical Name: N-Hydroxy-1-[(4-methoxyphenyl)methyl]-1H-indole-6-carboxamide
Purity: ≥98% (HPLC)
Citations (1)
Reviews (1)
Literature (4)

Biological Activity for PCI 34051

PCI 34051 is a potent and selective histone deacetylase 8 (HDAC8) inhibitor (IC50 = 10 nM). Displays >200 fold selectivity over HDAC isoforms 1, 2, 3, 6 and 10. Induces apoptosis in cell lines derived from T cell lymphomas or leukemias.

Compound Libraries for PCI 34051

PCI 34051 is also offered as part of the Tocriscreen Antiviral Library. Find out more about compound libraries available from Tocris.

Technical Data for PCI 34051

M. Wt 296.32
Formula C17H16N2O3
Storage Store at -20°C
Purity ≥98% (HPLC)
CAS Number 950762-95-5
PubChem ID 24753719
Smiles O=C(NO)C1=CC=C2C(N(CC3=CC=C(OC)C=C3)C=C2)=C1

The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.

Tocris products are intended for laboratory research use only, unless stated otherwise.

Solubility Data for PCI 34051

Solvent Max Conc. mg/mL Max Conc. mM
DMSO 29.63 100
1eq. NaOH 5.93 20

Preparing Stock Solutions for PCI 34051

The following data is based on the product molecular weight 296.32. Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Select a batch to recalculate based on the batch molecular weight:
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 3.37 mL 16.87 mL 33.75 mL
5 mM 0.67 mL 3.37 mL 6.75 mL
10 mM 0.34 mL 1.69 mL 3.37 mL
50 mM 0.07 mL 0.34 mL 0.67 mL

Molarity Calculator

Calculate the mass, volume, or concentration required for a solution.

*When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and CoA (available online).

Reconstitution Calculator

The reconstitution calculator allows you to quickly calculate the volume of a reagent to reconstitute your vial. Simply enter the mass of reagent and the target concentration and the calculator will determine the rest.


Dilution Calculator

Calculate the dilution required to prepare a stock solution.

References for PCI 34051

References are publications that support the biological activity of the product.

Pipalia et al (2011) Histone deacetylase inhibitor treatment dramatically reduces cholesterol accumulation in Niemann-Pick type C1 mutant human fibroblasts. Proc.Natl.Acad.Sci.U.S.A. 108 5620 PMID: 21436030

Balasubramanian et al (2008) A novel histone deacetylase 8 (HDAC8)-specific inhibitor PCI-34051 induces apoptosis in T-cell lymphomas. Leukemia 22 1026 PMID: 18256683

If you know of a relevant reference for PCI 34051, please let us know.

View Related Products by Product Action

View all Class I HDAC Inhibitors

Keywords: PCI 34051, PCI 34051 supplier, PCI34051, potent, selective, histone, deacetylase, 8, (HDAC8), inhibitors, inhibits, epigenetics, Apoptosis, Inducers, Class, I, HDACs, 4643, Tocris Bioscience

1 Citation for PCI 34051

Citations are publications that use Tocris products. Selected citations for PCI 34051 include:

Kim (2018) Suppression of TGFβ-mediated conversion of endothelial cells and fibroblasts into cancer associated (myo)fibroblasts via HDAC inhibition Br J Cancer 118 1359 PMID: 29695769

Do you know of a great paper that uses PCI 34051 from Tocris? Please let us know.

Reviews for PCI 34051

Average Rating: 5 (Based on 1 Review.)

5 Star
4 Star
3 Star
2 Star
1 Star

Have you used PCI 34051?

Submit a review and receive an Amazon gift card.

$50/€35/£30/$50CAN/¥300 Yuan/¥5000 Yen for first to review with an image

$25/€18/£15/$25CAN/¥75 Yuan/¥1250 Yen for a review with an image

$10/€7/£6/$10 CAD/¥70 Yuan/¥1110 Yen for a review without an image

Submit a Review

Filter by:

responder treated with 5 μM PCI34051 (HDAC 8 inhibitor) for 48 h. Cell lysates were analysed by western blot..
By Anonymous on 11/15/2019
Assay Type: In Vitro
Species: Human
Cell Line/Tissue: C3-TAg tumour cell

TGF beta high responder treated with 5 μM PCI34051 (HDAC 8 inhibitor) for 48 h. Cell lysates were analysed by western blot.

PMID: 29695769
review image

Literature in this Area

Tocris offers the following scientific literature in this area to showcase our products. We invite you to request* your copy today!

*Please note that Tocris will only send literature to established scientific business / institute addresses.

Epigenetics Scientific Review

Epigenetics Scientific Review

Written by Susanne Müller-Knapp and Peter J. Brown, this review gives an overview of the development of chemical probes for epigenetic targets, as well as the impact of these tool compounds being made available to the scientific community. In addition, their biological effects are also discussed. Epigenetic compounds available from Tocris are listed.

Cell Cycle & DNA Damage Repair Poster

Cell Cycle & DNA Damage Repair Poster

In normal cells, each stage of the cell cycle is tightly regulated, however in cancer cells many genes and proteins that are involved in the regulation of the cell cycle are mutated or over expressed. This poster summarizes the stages of the cell cycle and DNA repair. It also highlights strategies for enhancing replicative stress in cancer cells to force mitotic catastrophe and cell death.

Epigenetics in Cancer Poster

Epigenetics in Cancer Poster

This poster summarizes the main epigenetic targets in cancer. The dysregulation of epigenetic modifications has been shown to result in oncogenesis and cancer progression. Unlike genetic mutations, epigenetic alterations are considered to be reversible and thus make promising therapeutic targets.

Rheumatoid Arthritis Poster

Rheumatoid Arthritis Poster

Rheumatoid arthritis (RA) is a chronic destructive inflammatory autoimmune disease that results from a breakdown in immune tolerance, for reasons that are as yet unknown. This poster summarizes the pathology of RA and the inflammatory processes involved, as well as describing some of the epigenetic modifications associated with the disease and the potential for targeting these changes in the discovery of new treatments.